Literature DB >> 9833620

Effects of multiagent chemotherapy and independent risk factors in the treatment of high-risk GTT--25 years experiences of KRI-TRD.

S J Kim1, S N Bae, J H Kim, C T Kim, K T Han, J M Lee, J K Jung.   

Abstract

UNLABELLED: A retrospective and comparative study of high-risk gestational trophoblastic tumor (GTT) treated with different chemoregimen from 1971 to 1995 was performed and to find most effective chemotherapy regimen and independent risk factors. Three hundred seven patients in scoring over 8 points in WHO classification were categorized into high-risk group among 802 GTT cases received chemotherapy in the 2,418 GTD patients registered at KRI-TRD (Korean Research Institute for Gestational Trophoblastic Disease), Catholic University Medical College in Korea. Study groups of multiagent combination chemotherapy in 227 patients of the high-risk GTT were divided such as 49 cases of combination chemotherapy with MTX + folinic acid and Act-D, 40 cases of MAC regimen, 42 cases of CHAMOCA regimen, and 96 cases of EMA/CO. Initial tumor response according to hCG titer decrease was found in good response (log fall) 69.8%, of EMA /CO regimen group. On the other hand, good response was shown in only 24.5% of MTX + ACT-D, 32.5% of MAC regimen, and 52.4%, of CHAMOCA regimen respectively. Remission rate of EMA/CO regimen was 90.6% (87/96) and courses of chemotherapy until remission was 8.5+/-2.2. However, remission rate of other regimens of MTX + Act-D, MAC, and CHAMOCA were 63.3%, (31/49) 67.5% (27/40) and 76.2% (32/45) respectively, with 10.0+/-4.0, 10.7+/-4.3, 9.1+/-3.9 chemotherapy courses respectively until remission. Therefore, EMA/CO regimen groups were found to have low drug toxicity, early remission and a low failure rate. In the study of independent risk factors in the 165 cases of high-risk gestational trophoblastic tumor patients received EMA/CO regimen, stepwise Coxs proportional hazard's regression of prognostic factors using multivariate analysis revealed tumor age, number of metastatic organs, metastatic site and inadequate previous chemotherapy. According to the performance of fitted logistic regression model, the prediction rate of death and survival was 80.5%.
CONCLUSIONS: The most effective chemotherapy to high-risk GTT was EMA/CO regimen than other regimens. The following factors showed poor prognosis; 1) Tumor age is over 12 month, 2) more than 2 organs had metastatic lesion, 3) inadequate previous therapy that includes unplanned operation and inadequate previous chemotherapy.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9833620

Source DB:  PubMed          Journal:  Int J Gynaecol Obstet        ISSN: 0020-7292            Impact factor:   3.561


  6 in total

1.  The roles of surgery and EMA/CO chemotherapy regimen in primary refractory and non-refractory gestational trophoblastic neoplasia.

Authors:  Adnan Aydiner; Serkan Keskin; Sinan Berkman; Ergin Bengisu; Huseyin Ridvan Ilhan; Faruk Tas; Erkan Topuz
Journal:  J Cancer Res Clin Oncol       Date:  2012-02-23       Impact factor: 4.553

Review 2.  Gestational trophoblastic neoplasia: the management of relapsing patients and other recent advances.

Authors:  Naveed Sarwar; Edward S Newlands; Michael J Seckl
Journal:  Curr Oncol Rep       Date:  2004-11       Impact factor: 5.075

3.  Current chemotherapeutic management of patients with gestational trophoblastic neoplasia.

Authors:  Taymaa May; Donald P Goldstein; Ross S Berkowitz
Journal:  Chemother Res Pract       Date:  2011-05-11

4.  Chemotherapy and human chorionic gonadotropin concentrations 6 months after uterine evacuation of molar pregnancy: a retrospective cohort study.

Authors:  Roshan Agarwal; Suliana Teoh; Delia Short; Richard Harvey; Philip M Savage; Michael J Seckl
Journal:  Lancet       Date:  2011-11-28       Impact factor: 79.321

Review 5.  Gestational trophoblastic disease: a multimodality imaging approach with impact on diagnosis and management.

Authors:  Sunita Dhanda; Subhash Ramani; Meenkashi Thakur
Journal:  Radiol Res Pract       Date:  2014-07-13

6.  Gestational Trophoblastic Neoplasia Treatment at the Butaro Cancer Center of Excellence in Rwanda.

Authors:  Ignace Nzayisenga; Roanne Segal; Natalie Pritchett; Mary J Xu; Paul H Park; Edgie V Mpanumusingo; Denis G Umuhizi; Donald P Goldstein; Ross S Berkowitz; Vedaste Hategekimana; Clemence Muhayimana; Fidel Rubagumya; Temidayo Fadelu; Neo Tapela; Tharcisse Mpunga; Rahel G Ghebre
Journal:  J Glob Oncol       Date:  2016-04-13
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.